新型糖肽类抗生素达巴万星

Dalbavancin,a novel glycopeptide antimicrobial agent

达巴万星是一种新型半合成糖肽类抗生素,用于治疗革兰阳性菌引起的成人急性细菌性皮肤和皮肤组织感染(ABSSSI),抗菌谱包括耐甲氧西林金黄色葡萄球菌(MRSA)、甲氧西林敏感金黄色葡萄球菌(MSSA)、凝固酶阴性葡萄球菌(Co NS)和链球菌。与同类药物万古霉素、替考拉宁相比,抗菌活性相当或更强,每周1次静脉注射给药,患者顺应性更好。本文对其作用机制、抗菌活性、药动学、临床试验和安全性等进行简要介绍。

Dalbavancin is a new semisynthetic glycopeptide antimicrobial agent,indicated for the treatment of adult patients with acute bacterial skin and skin structure infections（ ABSSSI） caused by susceptible isolates of Gram-positive microorganisms. Dalbavancin shows antibacterial activities against Gram-positive bacteria including Staphylococcus aureus（ including methicillin-susceptible and methicillin-resistant strains）, coagulase negative Staphylococcus and Streptococcus anginosus group. The antimicrobial activity of dalbavancin is not inferior to vancomycin or teicoplanin. Dalbavancin is once-weekly intravenously administered,which is more convenient for patients. In this review,we briefly introduced the antimicrobial mechanism and activity,pharmacokinetics,clinical trials and safety of dalbavancin.